Login
Companies $ASND
$260.02 -$15.37 (5.58%) Live
Ascendis Pharma A/S logo

Ascendis Pharma A/S

ascendispharma.dk

What Do They Do?

Develops and sells TransCon-based medicines for people with endocrine rare diseases, and develops partnered therapies for other disease areas.

How Do They Make Money?

Sells its approved medicines to commercial customers, with payment tied to delivery. Collaboration and license agreements can bring in upfront, milestone and royalty payments; commercial supply under license agreements also generates revenue.

FY2025 revenue

Who Are Their Customers?

Healthcare providers prescribe its medicines, while specialty pharmacies distribute them in the United States. In Europe, the company sells directly in selected countries and uses sales and distribution partners in other markets; collaborations and license agreements also involve customers.

Do Revenues Turn Into Profits?

No. It lost EUR 228M in FY2025.

Operating income, FY2025
−19% of revenue
▲ +51% (Loss) vs FY2024 (−EUR 278.8M, −77%)
Net income, FY2025
−32% of revenue
▲ +40% (Loss) vs FY2024 (−EUR 378.1M, −104%)

How Are They Changing?

Growing. Revenue grew 92.6x in 4 years, from EUR 7.8M in FY2021 to EUR 720.1M in FY2025, about 210% a year.

More medicines on the market The company has moved from one marketed medicine to two, while continuing to develop candidates in endocrinology rare diseases and oncology.

Broader commercial reach The earlier report described building a commercial presence in North America and selected European countries through partners. The latest report describes integrated sales in the United States and selected European countries, with agreements covering additional international markets.

Who Do They Compete With?

Competes with Extend Biosciences, Nektar Therapeutics, OPKO Health, ProLynx, MBX Biosciences, and Serina Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support